
Partner
Michael Rohr
- Emerging Companies and Venture Capital
MICHAEL ROHR represents growth stage technology and life sciences companies from inception to exit. He counsels these companies on their general corporate and strategic needs, as well as on fundraising and transactional matters. Michael also counsels venture capital and growth/private equity funds, corporate venture investors, and strategic acquirors on investment transactions and acquisitions.
Experience
- Representative Matters
Representative transactions include:
Private
- Tectonic Therapeutic as primary outside counsel, including in its US$80 million Series A financing and merger with AVROBIO and simultaneous private placement of US$130.7 million.
- Alpheus Medical in its US$52 million Series B financing.
- Seismic Therapeutic in its US$101 million Series A financing and US$121 million Series B financing.
- Monolith Materials in its US$120 million Series C financing and US$300 million Series D financing.
- Gopuff in its US$1.15 billion private financing round.
- FIGUR8 in its US$25 million Series A-1 financing.
- General Catalyst in numerous investments, including:
- Eleanor Health’s US$50 million Series C financing.
- Series B investment in Index Systems.
- Zealand Pharma in its acquisition of Valeritas Holdings.
- automotiveMastermind in its US$45 million Series B financing and secondary tender offer.
- Brightree in its sale to ResMed for US$800 million.
- A unicorn technology company in its US$1 billion+ Series D financing, US$1.2 billion debt financing, and restructuring transaction.
- Frontline Technologies in its strategic acquisitions of multiple companies and sale to Roper Technologies for US$3.7 billion.
- Guidepost Growth Equity in its US$60 million Series B investment in Lucid Holdings and secondary tender offer.
- HighJump Software in its sale to Accellos (Accell-KKR) for US$237.5 million.
- Infraredx in its sale to Nipro Corporation.
- nToggle in its Series A financing, Series A-1 financing, and sale to Rubicon Project.
- Tarveda Therapeutics in its US$30 million Series D financings.
- Vesper Technologies in its US$18 million Series A financing and US$26 million Series B financing and acquisition by Qualcomm.
- InAuth in its Series A-1 financing with American Express.
- Avedro in its US$32 million recapitalization and Series AA financing, Series BB financing, and Series CC financing.
- The Cambridge Incubator (CIC) in its reorganization, and US$59 million Series A financing and US$80 million Series B financing.
- RxAdvance in its secondary investment and tender offer, joint venture, and subsequent Series A financing with Centene (CNC).
- CIMCON Lighting in its US$16 million Series B financing.
- Bessemer in its Series B investment in Toast.
- M33 Growth in multiple strategic growth equity investments/acquisitions, including Waterfield Energy Software, Titan Cloud Software, and AssuriCare.
Public
- Avedro in its US$70 million U.S. IPO.
- Biodel in its acquisition of Albireo.
- NetScout Systems acquisition of Danaher Corporation’s communications business unit for US$2.6 billion.
- Tectonic Therapeutic in its merger with AVROBIO and simultaneous private placement of US$130.7 million.
The above matters were handled prior to joining Sidley.
News & Insights
Credentials
Admissions & Certifications
- Massachusetts
Education
- Boston College Law School, J.D., 2011 (cum laude)
- Kansas State University, B.S. in Business Administration, 2008 (summa cum laude)